Drug Trial Radar · NCT06912165
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 31, 2024
Primary completion
Oct 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Zhejiang Wenda Pharma Technology LTD.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Conditions
- Brief Description of Focus of Study
Interventions
WD-890 tabletDrug
Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
WD-890 tabletDrug
Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
WD-890 tabletDrug
Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
PlaceboDrug
Participants will receive placebo QD from Week 0 through Week 16.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16Time frame: Screening up to Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.